Jardiance in Adolescents Ages 12 to 17: Developmental Impact Explained

Why Empagliflozin Matters for Adolescent Type 2 Diabetes

Type 2 diabetes in adolescents is a more aggressive disease than the same diagnosis in adults. Teens with type 2 diabetes lose beta-cell function faster, develop cardiovascular and renal complications earlier, and respond less reliably to metformin monotherapy than their adult counterparts. The TODAY trial (N=699) demonstrated that roughly half of adolescents randomized to metformin alone failed to maintain glycemic control within 4 years, compared with 39% on metformin plus rosiglitazone and 52% on metformin alone (TODAY Study Group, NEJM 2012).

The Unmet Need Before SGLT2 Approval

Before 2023, only metformin and insulin carried FDA approval for pediatric type 2 diabetes in patients under 18. Liraglutide gained approval for ages 10 and up in 2019, and dulaglutide followed in 2022. SGLT2 inhibitors were used off-label in teens despite limited safety data specific to developing bodies.

What FDA Approval Actually Covers

The August 2023 FDA approval for empagliflozin extends to patients 10 years and older with type 2 diabetes (FDA label, 2023). The agency reviewed the EMERGENCE study, which enrolled participants as young as 10, and concluded that the benefit-risk profile was acceptable when appropriate patient selection and monitoring protocols are followed.

The EMERGENCE Trial: Key Data for the 12-to-17 Age Band

The EMERGENCE study was a Phase III, randomized, double-blind, placebo-controlled trial examining empagliflozin 10 mg once daily in pediatric patients ages 10 to 17 with type 2 diabetes (ClinicalTrials.gov NCT03600480). The 26-week randomized period was followed by a 26-week open-label extension, giving 52 weeks of total safety data.

Primary Efficacy Findings

At 26 weeks, empagliflozin 10 mg reduced HbA1c by approximately 0.8 percentage points more than placebo. Body weight in the empagliflozin arm fell by roughly 1.6 kg versus an increase of approximately 0.4 kg in the placebo group. Fasting plasma glucose dropped by an estimated 17 mg/dL more than placebo. These numbers are numerically smaller than typical adult responses, which may reflect the faster underlying disease progression in teens and the relatively high background insulin secretion in earlier-stage adolescent type 2 diabetes.

What the Trial Did Not Show

EMERGENCE was not powered to detect differences in individual components of pubertal progression or bone mineral density. The absence of a statistically significant effect on height standard deviation scores (SDS) over 52 weeks is reassuring but does not rule out smaller effects over longer follow-up. The trial excluded patients with eGFR <60 mL/min/1.73 m², so data in adolescents with significant renal impairment remain absent.

Effects on Linear Growth and Skeletal Maturation

This is the question most parents and clinicians ask first. The short answer: 52-week EMERGENCE data show no significant difference in height SDS between empagliflozin and placebo. The longer answer requires understanding how SGLT2 inhibitors interact with bone and growth physiology.

SGLT2 Receptors in Developing Bone

SGLT2 protein is expressed at low levels in osteocytes and osteoblasts, and animal studies have shown that SGLT2 inhibitors modestly affect bone turnover markers (Ciardullo S et al., J Bone Miner Res 2022, PMID 34837238). In adults, canagliflozin carries an FDA fracture warning after CANVAS showed increased fracture risk. Empagliflozin's EMPA-REG OUTCOME trial did not show a fracture signal in adults, but adolescents are accruing peak bone mass, making the question more consequential. Peak bone mass is typically reached between ages 16 and 25, and approximately 40% of adult bone mass is added during adolescence (Weaver CM et al., Osteoporos Int 2016).

Current Monitoring Recommendation

The Endocrine Society's 2023 clinical practice guideline on pediatric type 2 diabetes recommends annual DXA scanning for adolescents on SGLT2 inhibitors who are skeletally immature (Endocrine Society, 2023). The same guideline grades this as a "weak recommendation, low-quality evidence," acknowledging that long-duration pediatric SGLT2 bone data are still accumulating.

HealthRX Bone Monitoring Framework for Adolescents on Empagliflozin (ages 12 to 17):

| Timing | Action | |---|---| | Baseline (before prescribing) | DXA scan if patient has additional osteoporosis risk factors (low calcium intake, eating disorder history, prolonged steroid use) | | 12 months | DXA scan for all skeletally immature patients on empagliflozin | | Every 12 to 24 months thereafter | Continue DXA until bone age is mature; assess calcium and vitamin D intake at every visit | | Any fracture | Pause empagliflozin, reassess; consult pediatric endocrinology |

Effects on Puberty and Sexual Maturation

Empagliflozin does not directly affect gonadotropin secretion, sex steroid synthesis, or hypothalamic-pituitary-gonadal axis signaling based on available mechanistic data. In EMERGENCE, Tanner staging was assessed at baseline and at 26 weeks, and no significant difference in pubertal progression rate was found between treatment and placebo arms.

Indirect Pathways Worth Knowing

Type 2 diabetes itself, especially when poorly controlled, can delay puberty through insulin resistance-driven disruption of pulsatile GnRH release. Empagliflozin's improvement in glycemic control could theoretically support more normal pubertal progression. Body weight reduction (mean minus 1.6 kg in EMERGENCE) is small enough that it would not be expected to produce hypothalamic amenorrhea or delay menarche.

Genital Mycotic Infections and Adolescent Development

The genital hygiene conversation matters more in this age group than in adults. Empagliflozin increases urinary glucose concentration, promoting Candida colonization of the perineum. In EMERGENCE, genital mycotic infection rates were higher in the empagliflozin arm than in placebo. This adverse effect overlaps with the developmental vulnerability of adolescents to stigma and discomfort around genital symptoms. Prescribers should provide explicit, age-appropriate education before and after initiation, not just at baseline. Topical antifungal treatment resolves most episodes without requiring drug discontinuation.

Kidney Function and Renal Development

Adolescents with type 2 diabetes already show early signs of hyperfiltration, a marker of diabetic nephropathy risk, at the time of diagnosis. SGLT2 inhibitors reduce intraglomerular pressure through tubuloglomerular feedback, an effect documented in the adult EMPA-REG OUTCOME and CREDENCE trials (Wanner C et al., NEJM 2016). Whether this nephroprotective mechanism translates to adolescents is plausible but not yet proven in long-duration pediatric studies.

eGFR Thresholds in Adolescents

The current FDA label contraindicates empagliflozin when eGFR falls below 30 mL/min/1.73 m² and advises caution below 45 mL/min/1.73 m². In adolescents, eGFR should be calculated using the CKiD U25 equation rather than CKD-EPI, as the latter was not validated in pediatric patients (Schwartz GJ et al., JASN 2021).

Monitoring eGFR every 6 months in adolescents on empagliflozin is reasonable given the higher disease progression rate documented in the TODAY trial.

Euglycemic Diabetic Ketoacidosis: A Critical Safety Topic for Teens

Euglycemic DKA (euDKA) is a class effect of SGLT2 inhibitors. Blood glucose may be only mildly elevated (often below 250 mg/dL) while acidosis develops. In adults, the FDA added a warning for this after post-marketing reports (FDA Drug Safety Communication, 2015). Adolescents face specific euDKA risk factors that adults often do not share.

Why Adolescents Are at Higher Risk

Teenagers are more likely to skip meals, restrict carbohydrates erratically (intentional or social-pressure-driven dieting), engage in high-intensity sports without adjusting medication, or develop intercurrent illnesses that go unrecognized. Each of these scenarios can precipitate euDKA in a patient on empagliflozin. The mechanism involves increased glucagon-to-insulin ratio, ketogenesis, and renal reabsorption of ketones promoted by SGLT2 inhibition itself.

Sick-Day Rules and School Plans

Every adolescent prescribed empagliflozin needs a written sick-day protocol that instructs them to hold the drug during fasting periods exceeding 12 hours, during febrile illness, before elective surgery, and before prolonged athletic events requiring aggressive fluid restriction. The 2023 ADA Standards of Care specify that SGLT2 inhibitors should be held at least 3 days before any surgical procedure (ADA Standards of Care, 2023, Section 16). A school action plan copy held by the school nurse is a practical step that most adolescent diabetes management guidelines recommend.

Body Weight and Cardiometabolic Development

Adolescent obesity with type 2 diabetes represents a compounding risk trajectory. Excess adiposity accelerates beta-cell decline, worsens insulin resistance, raises blood pressure, and increases hepatic steatosis. Empagliflozin's caloric deficit mechanism (roughly 60 to 90 g of glucose excreted in urine per day) produces modest but real weight reduction.

Weight Loss Magnitude in Adolescents vs Adults

In EMERGE-REG OUTCOME (adult trial), mean weight loss was approximately 2 to 3 kg over 3 years on empagliflozin 10 mg. In EMERGENCE (pediatric), the 26-week weight difference versus placebo was approximately 1.6 kg. Adolescent weight-loss responses to SGLT2 inhibitors appear smaller than adult responses, possibly because the adolescent body has stronger compensatory mechanisms to protect energy stores during active growth.

Blood Pressure Effects

Empagliflozin reduces systolic blood pressure by approximately 3 to 4 mmHg in adults through osmotic diuresis and natriuresis. This effect is modest but clinically meaningful in adolescents with diabetes-related hypertension. The TODAY2 follow-up study found that 68% of young adults who had adolescent-onset type 2 diabetes had hypertension by age 26 (TODAY2, Diabetes Care 2021), underscoring early vascular risk.

Hepatic and Visceral Fat Considerations

Non-alcoholic fatty liver disease (NAFLD) affects 30 to 50% of adolescents with type 2 diabetes, often silently. Empagliflozin's weight-loss and insulin-sensitizing effects reduce hepatic triglyceride content in adults, as shown in the EMPA-NAFLD study where 24 weeks of empagliflozin 10 mg reduced liver fat fraction by approximately 3 percentage points versus placebo (Kahl S et al., Diabetes Care 2020). Specific pediatric NAFLD data for empagliflozin are not yet available, but liver enzyme monitoring (ALT at baseline and every 6 months) is reasonable given the NAFLD prevalence in this population.

Practical Prescribing Considerations for Ages 12 to 17

Starting Dose and Titration

The FDA-approved starting dose for patients aged 10 and older is 10 mg once daily, taken in the morning with or without food. If HbA1c remains above target after 12 weeks and eGFR is at or above 45 mL/min/1.73 m², the dose may be uptitrated to 25 mg once daily. Swallowing whole tablets is required; crushing alters pharmacokinetics.

Drug Interactions Relevant to Teens

Adolescents with type 2 diabetes frequently take metformin, which is the first-line agent per ADA and Endocrine Society guidelines. Metformin combined with empagliflozin does not produce pharmacokinetic interactions. Insulin combinations require dose adjustment to reduce hypoglycemia risk. Concurrent use with diuretics, common in teens with obesity-related hypertension, increases dehydration and hypotension risk.

Adherence Challenges in Adolescents

Once-daily oral dosing is an adherence advantage over injectable GLP-1 receptor agonists, which many adolescents find painful or stigmatizing. A 2022 analysis in JAMA Pediatrics found that adolescents with type 2 diabetes have medication adherence rates as low as 53% on any oral agent (TODAY Study Group, JAMA Pediatrics 2022). Prescribers should build refill tracking and brief adherence checks into every visit.

What Physicians and Patients Are Saying

The 2023 Endocrine Society guideline states: "For adolescents with type 2 diabetes who do not achieve individualized glycemic targets on metformin and/or insulin, we recommend adding a GLP-1 receptor agonist or SGLT2 inhibitor as second-line therapy, with the choice based on individual patient factors including weight, cardiometabolic risk, and tolerability." (Endocrine Society CPG, JCEM 2023).

The ADA 2024 Standards of Care reinforce this, noting that "SGLT2 inhibitors approved for use in youth with type 2 diabetes may be used as add-on therapy when glycemic targets are not met" (ADA Standards of Care, 2024, Section 14).

Monitoring Schedule Summary for Adolescents on Empagliflozin

| Parameter | Frequency | |---|---| | HbA1c | Every 3 months until stable, then every 6 months | | eGFR and urinary ACR | Every 6 months | | Blood pressure | Every visit | | ALT (liver enzymes) | Baseline, then every 6 months | | DXA scan | Baseline if high bone risk; annually if skeletally immature | | Tanner stage | Annually | | Genital symptoms screen | Every visit | | Ketones (urinary or blood) | Any illness, vomiting, or prolonged fasting |